��ɫ��

��ɫ��

Events

Resources For

Abstract Details

Title Long-Term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis From ATTAIN, a Phase 3 Extension Study

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 002

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Marcelo C. Kremenchutzky, MD, FAAN (Lhsc - UWO) PRESENTER	No disclosure on file
Shifang Liu	No disclosure on file
	No disclosure on file
Serena W. Hung, MD	No disclosure on file
Ali Seddighzadeh	No disclosure on file
Vladimir Evilevitch	No disclosure on file
Frederik Barkhof, MD, PhD (Image Analysis Center)	Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI.